Lung disease diagnostic firm Biodesix last week announced the presentation of data at the ISPOR (International Society for Pharmaceutical and Outcomes Research) 2023 conference to provide evidence of the health economic benefits of its Nodify CDT and Nodify XL2 tests in the management of pulmonary nodules.
Boulder, CO-based Biodesix said that the poster presentations highlighted potential cost savings in both Medicare and commercially insured patient populations.
The analyses estimated cost savings in a hypothetical population of one million patients in a U.S. Medicare or commercial payer setting over a two-year timeline, predicting that the plans would save $600,000 to $3.9 million with use of the tests in the treatment pathways for managing pulmonary nodules.
The firm's blood-based Nodify Lung nodule risk assessment testing strategy consists of the Nodify XL2 and the Nodify CDT proteomic tests to evaluate the risk of malignancy in pulmonary nodules. The testing strategy enables physicians to better direct patients to the most appropriate course of action, the firm said.
